Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response
January 2026
in “
International Journal of Endocrinology
”
Studysummary This study found that using renin-angiotensin system-targeting antihypertensive agents or statins is associated with reduced serum HER2 levels, which may influence the risk of metabolic syndrome in women.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study involving 532 female patients found a significant association between higher serum HER2 levels and the prevalence of metabolic syndrome (MS). Women with MS had higher HER2 levels (9.25 vs. 8.10 ng/mL) and exhibited increased central obesity, hypertension, and glucose and lipid metabolism abnormalities. The likelihood of MS increased with higher HER2 levels, with a detection rate rising from 31.30% in the lowest quartile to 72.39% in the highest. HER2 levels were also linked to the use of certain medications, suggesting HER2 as a potential biomarker and therapeutic target for MS. Further research is needed to confirm these findings and explore treatment implications.
